GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

mosunetuzumab   Click here for help

GtoPdb Ligand ID: 12298

Synonyms: BTCT4465A | CD20-TDB [7] | Lunsumio® | mosunetuzumab-axgb | RG-7828 | RO7030816
Approved drug
mosunetuzumab is an approved drug (EMA & FDA (2022))
Compound class: Antibody
Comment: Mosunetuzumab (BTCT4465A) is an anti-CD20(MS4A1)/CD3e bispecific antibody [7] that was developed by Roche/Genentech to eliminate CD20+ve B cell malignancies by recruiting and activating effector T cells [1,4-5].
Classification Click here for help
Compound class Antibody
Approved drug? Yes. China NMPA (2024)  |  EU EMA (2022)  |  US FDA (2022)
International Nonproprietary Names Click here for help
INN number INN
10621 mosunetuzumab
Synonyms Click here for help
BTCT4465A | CD20-TDB [7] | Lunsumio® | mosunetuzumab-axgb | RG-7828 | RO7030816
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 760
Other databases
GtoPdb PubChem SID 479821089
Search PubMed clinical trials mosunetuzumab
Search PubMed titles mosunetuzumab
Search PubMed titles/abstracts mosunetuzumab